LBL-007 is under clinical development by BeiGene and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II drugs for Laryngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LBL-007 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LBL-007 overview

LBL-007 is under development for the treatment of advanced solid tumors, advanced lymphomas, renal cell carcinoma, metastatic colorectal cancer, cervical cancer, nasopharyngeal cancer, squamous and non-squamous non-small cell lung cancer, recurrent head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, esophageal squamous cell carcinoma and metastatic melanoma. The drug candidate acts by targeting lymphocyte activation gene 3 protein (LAG3). It is administered through intrapulmonary and intravenous routes.

The drug candidate was under development for the treatment of biliary tract cancer.

BeiGene overview

BeiGene is a biotechnology company. It specializes in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers Zanubrutinib, a small molecule inhibitor to treat various blood cancers and Sonrotoclax, a small molecule Bcl-2 inhibitor for treating chronic lymphocytic leukemia. BeiGene also provides Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. The company has operations in the US, Australia, Germany, Spain, Canada, Switzerland and Italy. BeiGene is headquartered in the Cayman Islands.

For a complete picture of LBL-007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.